Somatuline® Depot (lanreotide) – New indication
September 18, 2017 – Ipsen announced the FDA approval of Somatuline Depot (lanreotide) 120 mg injection, for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.
Download PDF
